CLBE-closed. new thread will be up in 15 minutes  

New Big Week. New Big Thread. GLTA

Link to the last thread!!
http://www.hotstockmarket.com/forums...ad.php?t=40588

Link the thread before that!!
http://www.hotstockmarket.com/forums...ad.php?t=40310

DD info Below.

http://finance.yahoo.com/q?s=clbe.ob

http://www.calbatech.com/

http://www.kdmedical.com/

http://www.molecula.com/

http://www.molecula.com/new/index2.html

http://www.solanamedspas.com/home_B.htm

http://www.biotechnologyireland.com/...Q=BF_COMP_9172

Adult, not embryonic, stem cells better for research

http://www.statenews.com/op_article.phtml?pk=36817

http://english.chosun.com/w21data/ht...510060016.html

Catholic Church Funds Adult Stem Cell Research

first link is a couple years old but gives crystal clear direction for now.

http://www.21stcenturysciencetech.co...stem_cell.html

CLBE: Financials Out!!! Profitable!!

BIOLOGY & MEDICINE

The Case for Adult Stem Cell Research


these individuals are all part of Calbatech

Kary Mullis, Ph.D. :: Nobel Laureate
Ph.D. Biochemistry, UC Berkeley
Dr. Mullis received the Nobel Prize in chemistry in 1993, for his invention of the polymerase chain reaction (PCR). The process, which Dr. Mullis conceptualized in 1983, is hailed as one of the monumental scientific techniques of the 20th century, one that revolutionized genetic science and engineering. PCR has also been an enormous commercial success. The original patent was sold to Hoffman LaRoche for $300 million and has generated more than a billion dollars in revenue from royalties.


Paul Heaney, Ph.D.
Ph.D. Medicinal Chemistry, Univ. of Glascow, Scotland

Dr. Heaney has held numerous positions within the life sciences industry, most recently as EVP of Research and Technology at Sequenom. Dr. Heaney's team was responsible for the development of the highly acclaimed and commercially successful chip-based MassARRAY™ Genotyping Platform and the MassARRAY™ 200K which can be multiplexed to more than one million DNA assays per day. While Head of Bioelectronics at the Sarnoff Corporation, Dr. Heaney's team was awarded a $12 million DARPA grant which led to the spin-out of Orchid BioSciences. Dr. Heaney holds more than 25 patents.

< Top of Page



David O'Bryan, Ph.D.
Ph.D. Medical Sciences/Biochemistry, BU Med School

Dr. O'Bryan is a former Senior VP at SmithKline Beecham Clinical Laboratories. He has more than 28 years experience in the clinical testing industry, including significant experience in developing new technologies. On behalf of SmithKline Beecham Clinical Laboratories he negotiated license agreements involving patented gene sequences used to diagnose diseases and secured the first license for nucleic acid testing. Dr. O'Bryan is also a recognized expert in laboratory instrumentation and automation in the commercial reference laboratory industry.

< Top of Page



Gerald Huth, Ph.D.
Ph.D. Physics/Electronics, Uppsala University, Sweden

In 1985, Dr. Huth founded Xsirius Scientific, Inc. Two subsidiaries, Xsirius Superconductivity, Inc. and Xsirius Photonics, Inc. had IPOs and traded on NASDAQ, with Xsirius Scientific having a market cap exceeding $100 million.To learn more about Dr. Huth and his inventions visit www.ghuth.com

< Top of Page



Jason Van Tassel, M.D.
Dr. Van Tassel is currently in medical practice specializing in Otolaryngology, Facial Plastic and Reconstructive Surgery in Los Angeles, CA. Dr. Van Tassel attended Georgetown University School of Medicine in Washington D.C., graduating with Honors in 1997. Upon completion of his residency, Dr. Van Tassel joined the faculty at the University of California at Irvine in the Department of Facial Plastic and Reconstructive Surgery, completing a fellowship in 2003. He is currently board certified in Otolaryngology and board eligible in Facial Plastic and Reconstructive Surgery. Prior to practicing medicine in LA, Dr. Van Tassel worked at Hybritech Inc., where he performed research investigating manufacturing processes related to monoclonal antibody test assays. In addition, Dr. Van Tassel also investigated retinal signal transduction pathways for the Dept. of Neurosciences at San Diego State.

Dear Fellow Shareholder:
We at CalbaTech, Inc. thank you for your investment in our Company. The goals at CalbaTech are two-fold: To acquire revenue generating Life Science "tools" companies, that provide products and platforms to researchers, forming a profitable base by which to provide the Company with cash flow and allow it to seek higher reward projects; and to develop those higher reward projects that will provide the opportunity for a greater upside to our shareholders. We believe we are well on our way to accomplishing both of these goals.
Research Reagents Division
In 2003, we acquired Molecula, LLC, a company in Sterling, Virginia, that sold transfection products. In 2004, we acquired KD Medical, a company in Columbia, Maryland, that supplied research products to more than 300 National Institute of Health (NIH) laboratories, as well as most of the major pharmaceutical companies. While both were generating revenue when acquired, neither was profitable. In the past year, we have worked diligently to make the Research Reagents Division the profitable base we intended.
The first step was to incorporate a new Molecula, Inc. in Nevada, and then combine the operations of Molecula and KD Medical into one facility to more efficiently capitalize on their synergistic operations. Next, marketing efforts were coordinated to take advantage of common markets. Finally, redundancies in the management teams of the two companies were eliminated. The result is that the Research Reagents Division reported a net profit for 2005 and again in the first quarter of 2006. Furthermore, this Division is reporting a 25% growth in revenue for the quarter ended March 31, 2006, as compared to the same period in 2005.
The next move is, literally, a move, into a new location. This Division will be moving into a new facility with two validated Class 100 clean rooms and a complete quality control laboratory that will be used to grow revenues in two different ways. One clean room will be used to increase the manufacturing capabilities of the KD Medical product offerings, so as to manufacture a higher quality of product, and to expand the current custom product offerings to the NIH as well as major universities and pharmaceutical companies. The second clean room will be utilized for other potential growth in revenue by allowing the Division to perform contract research for the many pharmaceutical companies located in this region.
Finally, the Research Reagents Division should also experience growth and greater profitability due to a recent understanding with a large media company to produce some of KD's routine media products. This is intended to allow KD to more aggressively sell these routine products, with greater profitability due to a decrease in redundant labor, and to enter markets that were previously unavailable due to cost competitiveness. This should result in an increase in revenues and allow KD to focus more attention to manufacturing custom products.
In summary, we believe that the Research Reagents Division has become a steady, growing, profitable foundation upon which we can build a greater return for our shareholders.

Cellular Therapies Division - LifeStem
In 2004, we purchased I-Stem from Dr. Jason R. Van Tassell, M.D. I-Stem owned the intellectual property to the Stem Cell Delivery Device, an endoscopic device capable of delivering adult stem cells directly to infarcted cardiac tissue. Dr. Van Tassel created the concept after hearing about an Illinois teenager who became a cardiac cripple after being shot in the heart by a nail gun. The teenager had adult stem cells injected into his blood stream resulting in cardiac tissue regeneration. While the teenager does not have completely normal cardiac function, the results were significant, allowing him functionality. Dr. Van Tassel reasoned that if stem cells injected into peripheral blood could cause significant cardiac tissue regeneration, then cells injected directly into the cardiac tissue would have even greater efficacy.
Subsequently the Company formed LifeStem, Inc., a wholly-owned subsidiary, to further I-Stem as well as to enter the new emerging field of banking adult stem cells for autologous use. This was determined after canvassing current stem cell banking services and realizing that there was a tremendous void to be filled, as the market had competitors at opposite poles. There are several companies collecting umbilical cord blood from newborns, which contain fertile stem cells, and there are other companies that are collecting autologous stem cells from adults in extremely inconvenient, invasive, costly, and time consuming ways. The former only helps those of the generation being born today whose parents have the foresight to take advantage of storing cord blood, and the latter does not provide non-invasive and convenient collection and storage of adult stem cells at a reasonable price.
We also determined that there were not any companies offering to collect adult stem cells from more than one tissue source. Some stem cells are more likely to develop into blood cells and similarly related tissues, while others are more likely to develop into bone, cartilage or muscle tissue. We therefore developed the process of harvesting stem cells in micro quantities to be cryopreserved for future transplantation into the client. We filed a patent application for our Stem Cell MicroBank(TM) Service, which is promulgated on the belief that it is unnecessary to collect an amount of stem cells sufficient to fully reconstitute one's entire immune system at the time of collection. LifeStem's Adult Stem Cell MicroBank(TM) is the only company to offer "micro" collections of stem cells from two different tissue sources thereby offering greater potential for treatments for multiple diseased conditions.
To a large degree, we believe that the adult stem cell collection and storage market mirrors the cosmetic surgery market, with its emphasis on proactive and preventative healthcare. People likely to have cosmetic surgery are concerned about quality of and longevity of life, they are health conscious, college-educated, and tend to seek non-traditional medical services. To this end, in December 2005, we signed a distribution agreement with Solana MedSpas, a developer and syndicator of medical spas, with 25 medspas currently open and operating and plans for more than 50 additional locations to open during 2006. In accordance with this agreement, adult stem cell collections will be performed at medspa locations using our Stem Cell Microbank(TM) Service. We are also working to contract with physician's offices to carry our Stem Cell MicroBank(TM) Service and believe that cosmetic surgeons, cardiologists, and orthopedists will be excellent distribution sites. With these agreements, we believe we will be ready to make an explosive entry into this marketplace as we perform the first collections in June.
First Quarter 2006 Financial Results/Stock Performance
The first quarter of this year is reflective of our belief in the CalbaTech model, as well as the actions we have taken over the past year. KD Medical, Molecula, and another of our other wholly-owned subsidiaries, Molecularware, Inc., all were profitable and as a whole experienced a 25% growth in revenue. LifeStem is primed for success as the pricing and cost structure of the Stem Cell Microbank(TM) Service will be profitable from each collection.

Why we Anticipate a Marketing PR and Financials this Week!!!

Ok gang. Here is the news that I promised. From my own correspondence with Paul, as well as a co-workers correspondence, I have been informed that a PR in regards to Calbatech’s marketing strategy is in the works for later this week or sometime next week per this email I received from a co-worker.

-----------------------------

M wrote:

Paul,
I hope all is well. I wanted to get in touch because I had received word from a fellow shareholder that Calbatech would be issuing PR sometime next week in regards to their Marketing strategy with the microbanks. I was hoping you might clarify this rumor for me. Is a PR to keep the shareholders up to date on this Marketing strategy in the works for the near future?
As always, thank you for your time and help! It is greatly welcomed and appreciated!
Subject: Re: Calbatech Marketing Strategy
I am trying to do something for them.

Paul
M wrote:

Trying to do something for them? Am I to assume that means something in the near future like this or next week in terms of letting the sharholders know what is going on?

Thanks,
Subject: Re: Calbatech Marketing Strategy
right; soonest. paul

----------------------------------

So that takes care of the PR in regards to the Marketing Strategy. If anyone has an opinion about this, please feel free to state it. M and myself feel it means that Paul was agreeing that a PR would be coming out this or next week. “right; soonest”

My own correspondence with Paul was in regards to the date of the financials and is below.


I think you hit the nail on the head. People want instant results.
This company is being built by smart, entrepreneurial, scientific-minded
people for the long term. The company had to test all aspects of its
microbank services -- remember what it is bringing to the marketplace is
both new and unique -- and it was more important to make sure everything
worked properly than to hit an arbitrary date for the launch.

The financials were issued last year on August 12 and these dates tend
to trend the same annually.

Hope this helps.

Paul Knopick

Spectre Trader wrote:

> Dear Mr. Paul Knopick,
>
> I am a concerned investor in Calbatech. I was originally turned onto
> the company through a very popular message board. I immediately was
> excited about the companies possibilities. In the last couple of weeks
> since the company issued their last PR, I have see the PPS drop while
> a great many people have begun to sell off shares. As you know, in the
> world of the Penny Stock Market, investors are hard to keep happy.
> They all want instant results. I know that no stock goes up every
> day, but after the market closed today, I fear that the stock has gone
> from having a pullback to a full downward trend. I am curious as to
> your thoughts as to why the company has left the shareholders in the
> dark on so many aspects of the microbank. All we were told was that it
> was delayed and here is a coupon!! To me, that needs to be clarified.
> Why was it delayed? What impact will the delay have on the companies
> profits? Why were the financials delayed? You have to understand that
> message boards have a great influence on a companies PPS. I guess I am
> looking for information and a response that can calm the storm waves
> that are currently going on! I look forward to your response.
>
> Sincerely,
>
> Spec

----------------------------------

OK. Last year the financials were released on Friday August 12th. This year the financials in my opinion will be coming out on the 11th if they release them on Friday, or Monday the 13th.

So what does all of this mean. IMHO, it means that we should be expecting a PR possibly sometime this week, but more than likely very early next week, followed with financials at the end of the week. I will remind everyone that it is fully LEGAL for a company to issue a release date for their financials, so when Paul says that it will trend the same as last year, it will. If you take this in combination with the fact that I personally have been in contact with several companies in regards to Email campaigns once the PR and Financials hit “and not the buy now crap like those P&D sites, but legit services that alert news to subscribers/members about undervalued companies and that’s all” and as of this moment, IMHO, we will begin the next run at the teens. With the recent MM’s consolidation, they now have enough shares to let this break past a dime, which is why IMHO, I say the teens.

Quest, as always, I know you will be confirming all of this correspondence with Paul. Please do so to validate it for the readers of this thread. Everyone else, take it with a grain of salt, but again, IMHO, this thing is about to go. I hope this is as good of news as I promised last night and was worth the wait. GLTA!!!!

AUSTIN, Jul 20, 2006 (M2 PRESSWIRE via COMTEX News Network) --


(OTCBB: CLBE) CalbaTech, Inc., a life sciences company, provides products and platforms to the research market for biotech and pharmaceutical companies, as well as to academic institutions. Through its three divisions, Molecular Applications, Research Reagents, and Cellular Therapeutics, as well as wholly owned subsidiaries, including Molecula, Inc.; KD Medical, Inc.; LifeStem, Inc.; and MolecularWare, Inc., the company is developing products and technologies in biological discovery. The Molecular Applications division has an active program of molecular biology applications and research, including pathogen microarrays, diagnostics, electronic-based DNA detection systems, and DNA sample preparation. The Research Reagents division provides cell and molecular biology reagents and related consumables. It develops and sells research reagents for cell transfection, DNA and RNA purification, protein expression, gene expression analysis, and other fundamental products. The Cellular Therapeutics division focuses on cellular applications, particularly those relating to the use of adult stem cells. It includes cell-based research projects for the delivery of cell-based clinical therapies.

As a trader, a very intelligent place to put your money, is where the money is flowing into. These are the kind of trades that you want to get into.

As the saying goes...follow the money!

http://www.solanamedspas.com/home_B.htm

Solana hopes to break out of the swell of spas with what it bills as a unique service: stem cell collection. Although the research is largely unproven, adult stem cells are seen by some as offering potential for treating heart disease, Parkinson’s disease, diabetes, Alzheimer’s disease and spinal cord injuries.

Solana has teamed with Irvine-based CalbaTech Inc. to collect stem cells at some of its spa locations. CalbaTech is a biotech company that’s part owner of Solana.

Solana draws stem cells from the abdomen for $3,000. The service is being offered in La Quinta and Pasadena. It plans to roll out stem cell collection to its 18 California locations, said Chief Executive John Buckingham, who codeveloped a spa management program at the University of California, Irvine.

Local investor John Garcia, who had his stem cells banked 10 years ago theold-fashioned way—they were painfully extracted from bone marrow—put Solana and CalbaTech together, Buckingham said. Garcia is founding principal of Tustin-based Angel Strategies LLC, which has invested in Solana.

Solana said it expects to have 38 spas open by the end of June and about 50 by the end of 2006.

Solana MedSpas’ overall strategy includes continually evaluating new technologies and services that will exclusively deliver leading edge products and services to its client / owners. A stunning example is their recent agreement with LifeStem, Inc., to offer its Stem Cell MicroBank Service through select locations in the Solana MedSpas network, making Solana MedSpas the first medical spa network to offer an adult stem cell collection service. Recent research indicates that autologous (one’s own) adult stem cells hold the potential for treatment, cure and possible prevention of numerous afflictions such as heart disease, Parkinson’s Disease, diabetes, Alzheimer’s disease, and spinal cord injuries. LifeStem, Inc., headquartered in Irvine, Calif., is a wholly owned subsidiary of CalbaTech, Inc. (OTC Bulletin Board: CLBE), a publicly traded emerging life sciences company concentrating on providing products and platforms to the research market for biotech and pharmaceutical companies and to academic institutions.